Inspire Medical Systems (NYSE:INSP) Stock Falls 6.2% - Time to Sell?

Key Points

• Inspire Medical Systems shares fell 6.2% to $68.63 in midday trading, with volume about 63% below its average.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $66.50; targets range from $60 to $80.
• The company exceeded quarterly EPS and revenue expectations, but revenue declined 7.6% year over year. Institutional investors own approximately 94.91% of the stock, while an insider recently reduced holdings by 4.83%.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) shares were down 6.2% during mid-day trading on Wednesday. The stock traded as low as $69.10 and last traded at $68.63. Approximately 400,517 shares were traded during trading, a decline of 63% from the average daily volume of 1,069,538 shares. The stock had previously closed at $73.18.

Analysts Set New Price Targets

INSP has been the subject of several recent analyst reports. Royal Bank Of Canada restated a "sector perform" rating and issued a $60.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Stifel Nicolaus lifted their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, September 11th. Piper Sandler boosted their target price on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a "neutral" rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. upped their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 4th. Finally, Mizuho raised their target price on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $66.50.

Inspire Medical Systems Stock Performance

The firm has a market cap of $2.01 billion, a PE ratio of 15.05, a PEG ratio of 5.29 and a beta of 0.70. The firm has a fifty day simple moving average of $62.28 and a two-hundred day simple moving average of $53.44.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analysts' expectations of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company's revenue for the quarter was down 7.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the company's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the sale, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Havemeyer Place LP purchased a new stake in Inspire Medical Systems during the fourth quarter valued at approximately $39,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company's stock worth $33,000 after purchasing an additional 580 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of Inspire Medical Systems by 194.0% in the 4th quarter. Hantz Financial Services Inc. now owns 685 shares of the company's stock worth $63,000 after purchasing an additional 452 shares during the period. Eurizon Capital SGR S.p.A. bought a new position in shares of Inspire Medical Systems during the 4th quarter valued at approximately $74,000. Finally, Versant Capital Management Inc increased its position in shares of Inspire Medical Systems by 379.0% during the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company's stock valued at $43,000 after purchasing an additional 758 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.